We investigated the clinico-biological features, outcomes, and prognosis in 949 patients with chronic lymphocytic leukemia according to age. No biological differences (cytogenetics by fluorescent in situ hybridization, IGHV, ZAP-70, CD38, NOTCH1, SF3B1) were found across age groups. Elderly patients (>70 years; n=367) presented more frequently with advanced disease (Binet C/Rai III-IV: 10/12% vs. 5/5%; p<.001), were treated less frequently (23.8% vs. 41.9% at 3 years; p<.001) and in most cases received no highly effective regimens thereby achieving a lower overall response rate (49% with 14% complete response vs. 69%with 31% complete response; p<.001). They also had shorter overall survival (6.6 vs. 13.3 years; p<.001) and higher diseaseunrelated mortality (34.9% vs. 6.9% at 10 years; p<.001). However, disease-attributable mortality was not significantly different between both groups. Combining Binet stage, ZAP-70, beta2-microglobulin and comorbidity two risk groups (low-risk: 0-1 parameters; high-risk: 2-4 parameters) with different overall survival (median: 6.8 vs.
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Introduction
Chronic lymphocytic leukemia (CLL), which is the most frequent form of leukemia in
Western countries, predominates in the elderly. 1, 2 Chemoimmunotherapy is considered the standard therapy for CLL. 3, 4 Unfortunately, most elderly patients do not tolerate intensive therapy, this leaving them without effective therapy. 5 In this context, new agents which target specific CLL pathogenic pathways (i.e., BCR-signal inhibitors) and with a good safety profile could represent an important progress in the treatment of CLL in the elderly. [6] [7] [8] Also important for improving their outcome is a better understanding of the disease characteristics and prognostic factors in elderly patients.
We report the clinico-biological characteristics of subjects with CLL according to agegroups in a large, single-institution series and focus on the outcomes and prognosis of elderly subjects (≥70 years) with CLL.
Methods

Patients and study design
In total, 949 patients diagnosed with CLL from January 1990 to December 2012 at the Hospital Clínic of Barcelona were evaluated. The study was approved by the local Institutional Review Board and was performed according to the Helsinki declaration.
Four groups of patients were distinguished: <59 years-old (n=345), 60-69 years-old (n=237), 70-79 years-old (n=234) and ≥ 80 years-old (n=133). Data collected at diagnosis included age, sex, functional status (PS), Binet and Rai stage, absolute lymphocyte count (ALC), immunoglobulin levels, cytogenetic abnormalities by fluorescent in situ hybridization (FISH), beta2-microglobulin (B2M), LDH levels, ZAP-70 and CD38 expression, IGHV mutational status and NOTCH1 and SF3B1 mutations using previously described methods. [9] [10] [11] Due to the retrospective nature of the study not all variables were available in all patients.
Treatment modalities varied over the years. Renal function at diagnosis was estimated by calculation of the creatinine clearance using the MDRD formula. For patients aged ≥ 70 years, Cumulative Illness Rating Scale (CIRS) was retrospectively assessed at the time of diagnosis (CIRS-D) and first line treatment (CIRS-T). 12, 13 Assessment of CIRS is detailed in the Supplemental Appendix.
Statistical methods
Baseline characteristics from both age groups were compared using Chi-square-or ANOVA-tests as appropriate. Cut-off levels for CIRS-D and CIRS-T were determined using maximally selected rank statistics. Time to first treatment (TTFT) was defined as time from diagnosis to date of initiation of first treatment or last follow-up. Overall survival (OS) was defined as the time between diagnosis and the date of death or last follow-up using the Kaplan-Meier method. Comparisons between different age groups and other covariates were performed by means of the log-rank test. Relative survival was calculated comparing the actuarial survival with the Spanish population matched by age, sex and calendar year of diagnosis. In patients aged 70 or older, multivariate analysis of prognostic factors for TTFT, OS and survival from first treatment was performed with Cox regression models after multiple imputation of missing data.
14 IGHV, NOTCH1 and SF3B1 mutations were not included in multivariate analysis because of the high number of missing data (>50%).
To avoid a bias in favor of responders, the impact of response on the OS was determined by a landmark analysis (9 months after treatment initiation). 15 Unadjusted pvalues <.05 were considered significant. Statistical methods are detailed in the Supplemental Appendix.
Results
Patient characteristics
The median age at diagnosis of the whole series of 949 patients was 65 years (range, 28-97), with 367/949 (39%) being 70 years of age or older. The median follow-up was 7.8
years. The main characteristics according to age groups are shown in Variables associated with OS in elderly patients are shown in Table 2 and Figure 2A -D.
In this cohort, beside standard prognostic variables comorbidity was also evaluated. The median comorbidity burden (CIRS) at diagnosis (CIRS-D) was 5 (range, 0-17). Elderly patients with a CIRS higher than 6 (CIRS-D>6) trended towards a shorter OS by univariate analysis (p=.064) ( Figure 2D ). The multivariate analysis showed independent prognostic value for clinical stage, B2M, ZAP-70, and comorbidity. High-risk FISH cytogenetics did not enter into the prognostic model. Table 2 ).
Discussion
The definition of elderly subjects is arbitrary and, as a result of the increasing lifeexpectancy of the general population, submitted to permanent revision. In our study, we defined elderly CLL patients as those >70 years of age, a cut-off that separated patients with marked differences in overall survival. Patients >70 years of age represented 39%
of the series, a proportion which has been maintained constant over the years (data not shown). This percentage is similar to that found in other studies 16 but smaller than that reported by the SEER (54%), 1 most likely reflecting differences between academic centers and population-based data. While the well-known male predominance in patients with CLL was corroborated in the overall series (58%), it was not observed in subjects >70 years of age (52%). The reasons for this disparity could include from differences in life expectancy (longer in women) to differences in access to medical care. In those patients with available information, biologic parameters such as ZAP-70, CD38, FISH cytogenetics, and IGHV mutational status or NOTCH1 and SF3B1 (Table1) were not differently distributed across age groups. Not surprisingly, elderly CLL patients presented with a poorer performance status and a worse renal function than younger ones, which limits treatment with intensive regimens.
There are few studies investigating the prognostic impact of comorbidity in CLL. Chronic lymphocytic leukemia in the elderly: Clinico-biological features, outcomes, and
proposal of a prognostic model, Baumann et al.
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Patients and Methods
Statistical methods
The cumulative illness rating scale (CIRS) 1 The CIRS was calculated as the sum of all co-morbid conditions, a number that theoretically ranges from 0 to 56. If a patient had two or more co-morbid conditions in the same body system, only the most severe was graded. The cut-off levels for CIRS-D and CIRS-T that had the greatest discriminative power in terms of overall survival were determined using maximally selected rank statistics (maxstat package, R software environment). 3 Time to first treatment (TTFT) was defined as time from diagnosis to date of initiation of first treatment or last follow-up. For TTFT analysis, CLL-unrelated deaths (i.e. any death before initiation of therapy) were considered as competing events. Cumulative incidence estimates were calculated using the CumIncidence.R function (cmprsk package, R) kindly provided by Dr. Scrucca, University of Perugia. 4 Multivariate regression analysis for TTFT also accounted for competing events using the crr-addson function, also provided by Dr. Scrucca.
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Overall survival (OS) was defined as the time between diagnosis and the date of death or last follow-up using the Kaplan-Meier method.
When evaluating specifically elderly patients who required therapy a landmark analysis (9 months after treatment) was performed to avoid bias in favor of responders. In the landmark analysis, patients who died or were lost to follow-up before the landmark time were not evaluated. 6, 7 Patients not evaluable and those presenting failure to treatment were grouped together.
Comparisons between different age groups and other covariates were performed by means of the log-rank test. Multivariate analysis of prognostic factors for OS was performed using Cox regression models.
In all multivariate analyses (TTFT and OS), multiple imputation of missing data was implemented using the Amelia package (R software environment). 8 Moreover, in all regression models the proportional hazard assumption was tested by plotting Schönfeld residuals against time.
Relative survival and CLL-attributable mortality were calculated using the relsurv package (R software environment). 9 Relative survival was defined as the ratio between the observed actuarial survival and the expected survival derived from a subset of the Spanish population matched by age, sex and calendar year of diagnosis, which was obtained from the Human Mortality Database. 10 Several models (additive, multiplicative and transformed) were tested as appropriate and their goodness-of-fit estimated using Brownian bridge statistics. 
